Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

Ake­bia $AK­BA slammed di­rect­ly in­to an un­ex­pect­ed brick wall Thurs­day morn­ing, as the biotech re­port­ed a crit­i­cal fail­ure in its sec­ond Phase III study of its ane­mia drug vadadu­s­tat.

The drug hit the pri­ma­ry and key sec­on­daries for ef­fi­ca­cy in a late-stage study pit­ting the drug against the in­jectable ESA dar­be­po­et­in al­fa among chron­ic kid­ney dis­ease pa­tients not on dial­y­sis. But it failed on the all-im­por­tant MACE non-in­fe­ri­or­i­ty stan­dard for safe­ty, track­ing time to first oc­cur­rence of ma­jor ad­verse car­dio­vas­cu­lar events.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN